Earnings Outlook For Marsh & McLennan

Marsh & McLennan (NYSE:MMC) is set to give its latest quarterly earnings report on Thursday, 2022-07-21. Here's what investors need to know before the announcement. Analysts estimate that Marsh & McLennan will report an earnings per share (EPS) of $1.87.

Marsh & McLennan (NYSE:MMC) is set to give its latest quarterly earnings report on Thursday, 2022-07-21. Here’s what investors need to know before the announcement.

Analysts estimate that Marsh & McLennan will report an earnings per share (EPS) of $1.87.

Marsh & McLennan bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.16, which was followed by a 4.4% drop in the share price the next day.

Here’s a look at Marsh & McLennan’s past performance and the resulting price change:

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 2.14 1.34 0.98 1.42
EPS Actual 2.30 1.36 1.08 1.75
Price Change % -4.4% 2.01% 0.68% 1.03%

eps graph

Stock Performance

Shares of Marsh & McLennan were trading at $153.28 as of July 19. Over the last 52-week period, shares are up 5.07%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

To track all earnings releases for Marsh & McLennan visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

CBD Giant’s Challenging Year: Q4 Net Sales Slide By 27% But Net Loss Narrows 67% YoY

cbdMD reported a 27% year-over-year drop in net sales for the fourth quarter of 2023, totaling $5.7 million. The company attributed the decline to industry trends, reduced marketing spend, and lower wholesale pricing for its new high-strength products. For the full fiscal year 2023, net sales reached $24.2 million, down from $35.4 million in the previous year. Gross profit for the year was approximately $15 million, a decrease from $22.3 million in fiscal 2022. The company reported a net loss of about $23 million, compared to $70 million in 2022. Operating expenses fell to $24.2 million from $40 million in the prior year. cbdMD's working capital on September 30, 2023, was $3.4 million, down from $10.7 million on the same date in 2022. The company also launched its hempMD and ATRx brands in 2023, expanding its product channels into Amazon and other consumer products channels.

YCBD